Newsletter

207940 - Samsung Biologics Co., Ltd.

207940 Summary
Biopharma
Stock Price & Overview
₩1,466,000 +19,000 (+1.31%) Close · Sep 7, 2026 KST
KOSPI | ₩KRW | Close: ₩1,466,000  ≈ US$1,047  ·  Market cap ₩67.9tn (≈ $48.5bn)
Home › 207940 › Filings

Change in the Largest Shareholder's Holdings

DART
Samsung Biologics Co., Ltd.
Filed Sep 7, 2026 KST · Ownership · receipt 20260907800372

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 최대주주등소유주식변동신고서

207940

Price
₩1,466,000
Change
+1.31%
Market cap
₩67.9tn
Prev. close
₩1,447,000
207940 SummaryCompare to Peers

207940 data on kstock

Financials
11 fiscal years

Every figure is taken from Samsung Biologics Co., Ltd.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

kstock analysis on 207940

Samsung Biologics: The Eight-Year Plan Costs Less Per Year Than It Already Earns

Sep 5, 11:02 AM

Samsung Biologics Asks Shareholders For ₩3tn Five Weeks After Saying It Would Borrow

Aug 28, 4:16 PM

Samsung Biologics: The Spin-Off Left A Better Company And An Unusable Track Record

Aug 28, 4:03 PM

Samsung Biologics: ₩2.7tn For A Swiss Peptide Maker With Three Years Of Losses

Aug 28, 4:00 PM
All 207940 analysis

More 207940 filings

Investor Relations Event

09/03/26

Acquisition of Shares in Another Company

08/31/26

Large business group status disclosure — quarterly, individual company

08/31/26

Investor Relations Event

08/28/26

Material event report (paid-in capital increase)

08/28/26

Record date set, shareholder register closed

08/28/26
All 207940 filings